Search

Your search keyword '"Zielinski, R."' showing total 12 results
Start Over Author "Zielinski, R." Publisher elsevier ltd
12 results on '"Zielinski, R."'

1. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis

Author

Banks, S., Hong, W., Degeling, K., Shapiro, J., Thomson, B., Ko, H.S., Ananda, S., Jalali, A., To, Y.H., Loveday, B., McLachlan, S.-A., Knowles, B., Fox, A., Michael, M., Wong, R., Burge, M., Clarke, K., Pattison, S., Nikfarjam, M., Zielinski, R., Day, F., Chee, C.E., Nagrial, A., IJzerman, M., Gibbs, P., and Lee, B.

Published
2024
Full Text
View/download PDF

6. 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

Author

Horvath, L.G., Davis, I.D., Martin, A., Zielinski, R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D., Parnis, F., North, S., Marx, G.M., McCaffrey, J.A., McDermott, R.S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K.N.N., Stockler, M.R., and Sweeney, C.

Published
2023
Full Text
View/download PDF

7. Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial.

Author

North S.A., Caffrey J.M., McDermott R., Parnis F., Sweeney C.J., Zielinski R., Thomson A., Tan T.H., Sandhu S.K., Reaume M.N., Pook D.W., Stockler M.R., Martin A.J., Dhillon H., Davis I.D., Chi K.N., Chowdhury S., Horvath L.G., Lawrence N.J., Marx G.M., North S.A., Caffrey J.M., McDermott R., Parnis F., Sweeney C.J., Zielinski R., Thomson A., Tan T.H., Sandhu S.K., Reaume M.N., Pook D.W., Stockler M.R., Martin A.J., Dhillon H., Davis I.D., Chi K.N., Chowdhury S., Horvath L.G., Lawrence N.J., and Marx G.M.

Abstract

Background: We previously reported that treatment with enzalutamide (ENZA) rather than an older non-steroidal anti-androgen (NSAA: bicalutamide, nilutamide, or flutamide), resulted in longer overall survival when added to standard first-line treatment, with or without concurrent early docetaxel, in mHSPC (hazard ratio 0.67, 95% CI 0.52 to 0.86, p = 0.002, NEJM 2019). Here we report effects on HRQL. Method(s): HRQL was measured with the EORTC QLQ-C30 and PR25 at weeks 0, 4, 12, and then 12-weekly until clinical progression. We used mixed models for repeated measures to calculate the least squares mean difference (LSMD), 95% CI, and p-value for comparisons of the randomly assigned groups for all assessments from week 4 to 156. For each analysis of deterioration-free survival, the endpoint was defined a-priori as the earliest of death, clinical progression, cessation of study treatment, or a 10-point worsening from baseline (minimum clinically important difference on scales scored from 0 to 100) in the pertinent HRQL sub-scale: physical functioning (PF), global health and quality of life (GHQL), cognitive functioning (CF), and fatigue; p-values were based on the log-rank test. Result(s): Completion of HRQL forms in 1016 men with a baseline assessment of HRQL (1125 randomised) ranged from 94% at week 12 to 78% at week 156. Random assignment to ENZA v NSAA was associated with modest impairments (LSMD, 95% CI) from week 4 to 156 in fatigue (5.0, 3.3 to 6.7, p < 0.0001), CF (3.9, 2.4 to 5.4, p < 0.0001), and PF (2.5, 1.2 to 3.8, p = 0.0002), but not GHQL (1.1, -0.4 to 2.6, p = 0.16). Deterioration-free survival rates at 3 years favoured ENZA over NSAA for GHQL (32% v 18%, p < 0.0001), CF (33% v 21%, p = 0.0003), and PF (31% v 22%, p = 0.001), but not fatigue (26% v 18%, p = 0.1). The effects of ENZA on HRQL were relatively stable over time and unaffected by treatment with concurrent early docetaxel. Conclusion(s): The addition of ENZA maintained GHQL and improved deteriora

Published
2020

10. LBA53 - Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

Author

Stockler, M.R., Martin, A.J., Dhillon, H., Davis, I.D., Chi, K.N., Chowdhury, S., Horvath, L.G., Lawrence, N.J., Marx, G.M., Caffrey, J Mc, McDermott, R., North, S.A., Parnis, F., Pook, D.W., Reaume, M.N., Sandhu, S.K., Tan, T.H., Thomson, A., Zielinski, R., and Sweeney, C.J.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results